Scientists Just Found a New, Incredibly Rare Blood Type
The French Blood Establishment (EFS), the country's sole civilian blood transfusion organization, announced the discovery over the weekend. The blood type, nicknamed 'Gwada negative,' was found in a French woman originally from Guadeloupe. It's the 48th distinct blood group system to be established.
'This discovery was officially recognized in early June in Milan by the International Society of Blood Transfusion,' the EFS said in a statement released on LinkedIn Friday.
The 'Man With the Golden Arm': Blood Donor Who Saved Millions Dies at 88
It's taken a long while for this recognition to happen. Researchers at the EFS first noticed an unusual antibody in the woman's blood in 2011, after she provided a sample for routine examination before a surgery in her early 50s. But they simply didn't have the resources or technology needed at the time to look further into it. Finally, in 2019, they were able to perform 'high-throughput DNA sequencing' of the woman's genetics, which confirmed she possessed a unique blood-related mutation inherited from both her parents.
Her blood type appears to be the result of having both copies of this mutation, since her siblings have one copy and don't have it. The blood type is formally called PIGZ, with Gwada negative being a reference to the woman's Guadeloupean origin (Guadeloupe is an French island region in the Caribbean). So far, she seems to be one of a kind.
'She is the only person in the world who is compatible with herself,' Thierry Peyrard, a medical biologist at the EFS who helped discover the blood type, told the AFP.
Donated Blood Is Safe No Matter a Person's Sex, Large Trial Finds
Blood types refer to the particular combinations of antigens that cover our red blood cells. The most commonly found antigens belong to the ABO blood group, but scientists have discovered over 600 separate antigens that can be sorted into dozens of blood groups. Knowing our blood type is important, since our body's immune system can generate antibodies that attack blood cells from someone with a blood type incompatible with ours. This not only complicates blood donation but pregnancy. So aside from simple curiosity, categorizing Gwada negative and other rare blood types can be medically vital.
'Discovering new blood types means offering patients with rare blood a better level of care,' the EFS said.
Peyrard and his colleagues are now hoping to find others with the woman's blood type, and will first plan to look for it among blood donors in Guadeloupe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
35 minutes ago
- Gizmodo
This Bright Dot May Be an Entirely New Type of Space Object
At first, the dot looked like any other star. Then the astrophysicists switched to polarized light and found themselves looking at an entirely unexpected sight. 'Everything else disappeared, even the bright central black hole, and only this little dot remained,' Elena Shablovinskaia, an astrophysicist at Universidad Diego Portales in Chile and the Max Planck Institute for Radio Astronomy in Germany, told Gizmodo. Shablovinskaia's team believes they've discovered an entirely new kind of space object, which they've dubbed 'Punctum.' Like its name, Latin for 'point' or 'dot,' Punctum is a compact, bright splotch of light in space—but it's only visible at millimeter wavelengths and harbors an unusually organized magnetic field. A paper on Punctum has been accepted for publication in Astronomy & Astrophysics and is currently available on arXiv. The team wanted to show that Punctum is simply an unusual example of a known phenomenon, such as a magnetar or a supernova remnant. NGC 4945, where Punctum lives, is a nearby galaxy known for hosting an active population of baby stars—so it made sense to assume Punctum was one of them. After all, NGC 4945 resides so close to the Milky Way that astrophysicists thought they had a solid grasp of the galaxy. We couldn't have missed something 'hiding in plain sight,' as Shablovinskaia put it…could we? But the more they tried to force Punctum into established astrophysical wisdom, the more it seemed to defy it. For example, Punctum disappeared when the team checked the same region using X-ray or radio telescopes, appearing only in the millimeter spectrum with the Atacama Large Millimeter/submillimeter Array (ALMA). ALMA's ability to capture polarized light also revealed Punctum's weird magnetic field to the scientists, adding to its mystery. Astronomers Calculate Universe's Age With Atacama Desert Telescope 'So we compared its brightness, polarization, and spectrum to every extreme object we could think of—magnetars, pulsars, star-forming regions, and black hole jets,' Shablovinskaia recalled. 'Nothing matched.' But accepting that they'd struck something entirely new only raised more questions. What exactly is it? Where does Punctum—10,000 to 100,000 times brighter than magnetars and 10 to 100 times brighter than most supernovas—get its light? Could it be connected to a black hole or a neutron star? For Shablovinskaia, the best shot at finding the answer might be to investigate Punctum's strange polarization, 'basically a fingerprint of the magnetic environment,' she said. After all, the disturbingly neat alignment of the light waves around Punctum was what alerted the team to the object's weirdness. 'Usually, when light is produced in cosmic environments, it comes out mixed and disordered because the magnetic fields are tangled,' she explained. 'If we can measure [Punctum's magnetic field] at more wavelengths or watch how it changes over time, we can start to figure out what powers Punctum and whether it links to known astrophysical objects.' 'Punctum shows us the universe can still surprise us in places we thought we understood well,' Shablovinskaia said. 'For me, it's a reminder that astronomy is far from finished; we're still just beginning to discover the full variety of cosmic objects out there.' The new research marks another strong example of multi-messenger astronomy, in which astronomers use different kinds of signals to investigate a single source. Recently, astronomers found an ultramassive black hole using gravitational lensing. In this case, the scientists studied a specific behavior of light—polarization—alongside more conventional methods to double-check their results.
Yahoo
an hour ago
- Yahoo
ONWARD Medical Receives FDA IDE Approval to Initiate the Empower BP Pivotal Study with the ARC-IM System
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The investigational device exemption (IDE) allows initiation of a global pivotal study designed to assess the safety and efficacy of the ARCIM System®, an implantable neurostimulation technology developed to address blood pressure instability after spinal cord injury (SCI). Managing blood pressure instability is a major unmet need after SCI, with a significant impact on cardiovascular health and quality of life. Approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe are expected to participate. EINDHOVEN, The Netherlands, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury and other movement disabilities, today announces that the US Food and Drug Administration (FDA) has approved an investigational device exemption for the ARC-IM System. With this approval, the Company can initiate the Empower BP pivotal study to assess the safety and efficacy of its implantable spinal stimulation system to address blood pressure instability after SCI. Empower BP is the Company's second global pivotal study, and the first to evaluate the implantable ARC-IM System. The randomized, double-blinded, sham-controlled study is expected to involve approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe, with first patient enrollment anticipated before the end of the year. The study will target participants with injuries at spinal cord levels C2-T6, injury severities of AIS A-D, and blood pressure instability characterized by chronic orthostatic hypotension (OH) and episodes of autonomic dysreflexia (AD). 'This is an important milestone for ONWARD and the SCI community,' said Dave Marver, CEO of ONWARD. 'Our ARC-IM System is designed to address several unmet needs, including blood pressure instability which is a major recovery target after spinal cord injury. With this IDE approval, we continue to advance our innovation pipeline and inspire realistic hope in restoring autonomic functions and independence after SCI and other movement disabilities.' Over 50% of people with SCI experience blood pressure instability, affecting nearly 350,000 people in the US and Europe.1 Blood pressure instability and persistent low blood pressure can threaten neurological recovery and negatively impact cardiovascular health and quality of life. The most frequent symptoms include dizziness, lightheadedness, blurred vision and fatigue.2 'Blood pressure instability, especially chronic low blood pressure, is one of the most hidden and unrecognized functional complications of spinal cord injury,' explains Dr. James Guest, neurosurgeon and Professor of Neurological Surgery at the University of Miami. 'It leaves people feeling unwell and can significantly impact their overall quality of life. Blood pressure instability also increases the risk of cardiovascular disease, making addressing this unmet need critical for improving the long-term outcomes of SCI.' The ONWARD ARC-IM System is an implanted neuromodulation platform designed to deliver targeted and personalized spinal cord stimulation. It is the first neuroprosthetic system designed to manage blood pressure instability in people with SCI. It comprises the implanted ONWARD Neurostimulator (IPG) and the ARC-IM Thoracic Lead. The ARC-IM Thoracic Lead is optimized for surgical placement in a specific region of the thoracic spinal cord, called the 'Hemodynamic Hotspot'. The location was first discovered by the Company's research partners at the Swiss Federal Institute of Technology Lausanne (EPFL), Centre Hospitalier Universitaire Vaudois (CHUV), and the University of Calgary in a study published in Nature in January 2021.3 In December 2022, the Company announced positive top-line interim clinical results from its feasibility studies showing improved blood pressure regulation and improved hemodynamic stability after SCI. In addition to immediate and sustained improved blood pressure levels, participants taking anti-hypotension drugs prior to the study significantly reduced or discontinued their medication. Participants also reported improved general well-being and a reduction in orthostatic hypotension, including reduced dizziness and increased energy. Detailed interim results from these studies are expected to be published later this year. Managing blood pressure instability is among the major unmet needs for which the FDA has awarded the Company one of its 10 Breakthrough Device Designations. This award is reserved for novel, cutting-edge therapies addressing unmet needs and provides potential regulatory and reimbursement benefits. To stay informed about ONWARD's research studies, technologies, and the availability of therapies in your area, please complete this webform. About ONWARD Medical ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries, and other movement disabilities. Building on over a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company developed ARC Therapy. It has subsequently been awarded 10 Breakthrough Device designations from the FDA. The Company's ARC-EX® System is cleared for commercial sale in the US. The Company is also developing an investigational implantable system called ARC-IM, which can be paired with a brain-computer interface (BCI) to restore thought-driven movement. Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY). For more information, please visit For Media Inquiries: Sébastien Cros, VP Communications media@ For Investor Inquiries: investors@ Notes and references: 1. Katzelnick CG et al. Blood Pressure Instability in Persons With SCI: Evidence From a 30-Day Home Monitoring Observation. Am J Hypertens. 2019 Sep 24;32(10):938-944 2. Carlozzi, N. E. et al. Impact of blood pressure dysregulation on health-related quality of life in persons with spinal cord injury: development of a conceptual model. Arch. Phys. Med. Rehabil. 94, 1721–1730 (2013) 3. Squair, J.W. et al. Neuroprosthetic baroreflex controls haemodynamics after spinal cord injury. Nature 590, 308–314 (2021) Forward-Looking Statements Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Yahoo
2 hours ago
- Yahoo
Clean and harmonised CRM data vital for AI model training
As healthcare entities move towards the deployment of artificial intelligence (AI) models to streamline patient engagement, being acquitted of good customer relationship management (CRM) system data is of rising importance, an expert has said. In April 2025, the UK National Health Service (NHS) released guidance on the importance of using high-quality data in training AI models. The guidance highlighted that poor quality data can lead to unintended biases and other inaccuracies that may stymy the effectiveness of AI models used for varying functions in healthcare systems. CRM data includes information on patient demographics, individuals' medical history, insurance information, billing details, and more. The consolidation of this data is intended to improve patient engagement, personalise care, and track individuals' medical history. A 2022 report indicated that revenue streams from 44% of healthcare respondents were directly affected bypoor quality CRM data. In addition, 69% of respondents said their organisations did not pursue or complete potentially valuable initiatives due to low-quality CRM data. According to Rachel Mak-McCully, senior data scientist at digital twin developer the cleaning and harmonisation of CRM datasets is not an area that is given enough consideration – despite its significant influence on AI models being deployed in healthcare. 'In thinking about clean data, there's a few issues, including how accurate and comprehensive the data is,' Mak-McCully told Medical Device Network. 'In the US, we have a very fractured medical system, so the information that you get about someone may be quite fractured.' Fractured data can relate to data that is missing because it hasn't been collected at the same time or stored together, Mak-McCully said, or in the sense that it's been measured in different ways. 'Imagine the data cleaning process as a spreadsheet. You might have a lot of different columns that are named differently, but they're the same thing. You want to make sure that all of those are harmonised into the same column,' Mak-McCully said. 'And you want to make sure that the units that you're measuring across a range of different data sources are the same. The ultimate goal is to have a clean, tabular dataset at the end that incorporates all relevant sources of data, so that a single, clean source of data can be used to train your AI model.' Mak-McCully concludes that while there is a lot of talk about the performance of AI models in healthcare and other areas, such as the new benchmarks that have been made, very few people talk about the underlying data. 'For us to clearly communicate what it is that we're doing, the implications of that and for people to understand how data is used, particularly in healthcare, is a really important conversation.' "Clean and harmonised CRM data vital for AI model training" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
